PT2877177T - Derivados do tipo azaindazole ou diazaindazole para tratamento da dor - Google Patents

Derivados do tipo azaindazole ou diazaindazole para tratamento da dor

Info

Publication number
PT2877177T
PT2877177T PT137458139T PT13745813T PT2877177T PT 2877177 T PT2877177 T PT 2877177T PT 137458139 T PT137458139 T PT 137458139T PT 13745813 T PT13745813 T PT 13745813T PT 2877177 T PT2877177 T PT 2877177T
Authority
PT
Portugal
Prior art keywords
azaindazole
derivatives
treating pain
diazaindazole
type
Prior art date
Application number
PT137458139T
Other languages
English (en)
Portuguese (pt)
Inventor
Sokoloff Pierre
Cachoux Frédéric
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PT2877177T publication Critical patent/PT2877177T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT137458139T 2012-07-27 2013-07-29 Derivados do tipo azaindazole ou diazaindazole para tratamento da dor PT2877177T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305922.2A EP2689778A1 (en) 2012-07-27 2012-07-27 Derivatives of azaindoles or diazaindoles for treating pain

Publications (1)

Publication Number Publication Date
PT2877177T true PT2877177T (pt) 2017-02-06

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137458139T PT2877177T (pt) 2012-07-27 2013-07-29 Derivados do tipo azaindazole ou diazaindazole para tratamento da dor

Country Status (28)

Country Link
US (1) US9381195B2 (OSRAM)
EP (2) EP2689778A1 (OSRAM)
JP (2) JP6456823B2 (OSRAM)
KR (1) KR102120505B1 (OSRAM)
CN (1) CN104684554B (OSRAM)
AU (1) AU2013294920B2 (OSRAM)
BR (1) BR112015001502B1 (OSRAM)
CA (1) CA2879595C (OSRAM)
CY (1) CY1118478T1 (OSRAM)
DK (1) DK2877177T3 (OSRAM)
ES (1) ES2612349T3 (OSRAM)
HR (1) HRP20170104T1 (OSRAM)
HU (1) HUE032919T2 (OSRAM)
IL (1) IL236917A (OSRAM)
LT (1) LT2877177T (OSRAM)
MA (1) MA37866B1 (OSRAM)
MX (1) MX363605B (OSRAM)
MY (1) MY183398A (OSRAM)
NZ (1) NZ705253A (OSRAM)
PL (1) PL2877177T3 (OSRAM)
PT (1) PT2877177T (OSRAM)
RS (1) RS55646B1 (OSRAM)
RU (1) RU2640046C2 (OSRAM)
SI (1) SI2877177T1 (OSRAM)
TN (1) TN2015000034A1 (OSRAM)
UA (1) UA116107C2 (OSRAM)
WO (1) WO2014016433A1 (OSRAM)
ZA (1) ZA201501209B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
AU2015328307B2 (en) 2014-10-06 2019-11-21 Apm Therapeutics 1, Inc. Triazolopyridine compounds and methods for the treatment of cystic fibrosis
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. Trk阻害薬耐性がんにおける点変異およびそれに関連する方法
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (ja) * 2016-10-31 2018-05-03 塩野義製薬株式会社 TrkA阻害活性を有する縮合複素環および縮合炭素環誘導体
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20220259199A1 (en) * 2018-05-02 2022-08-18 Jw Pharmaceutical Corporation Novel heterocycle derivative
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
TW202448883A (zh) * 2023-05-24 2024-12-16 大陸商長春金賽藥業有限責任公司 Fgfr2/3選擇性抑制劑、藥物組合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2283961A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
HUP0301183A3 (en) 2000-06-22 2006-02-28 Pfizer Process for the preparation of pyrazolopyrimidinones
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
KR101011957B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 P38 mαp 키나아제 저해제 및 이의 사용 방법
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
SI2120932T1 (sl) * 2006-12-20 2014-09-30 Nerviano Medical Sciences S.R.L. Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
PL2176231T3 (pl) * 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
EP2373626B1 (en) 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain

Also Published As

Publication number Publication date
DK2877177T3 (en) 2017-02-06
IL236917A (en) 2016-11-30
MX2015001009A (es) 2015-06-04
TN2015000034A1 (en) 2016-06-29
EP2877177A1 (en) 2015-06-03
WO2014016433A1 (en) 2014-01-30
EP2689778A1 (en) 2014-01-29
KR102120505B1 (ko) 2020-06-08
US9381195B2 (en) 2016-07-05
US20150190394A1 (en) 2015-07-09
CN104684554A (zh) 2015-06-03
CA2879595A1 (en) 2014-01-30
HRP20170104T1 (hr) 2017-03-24
BR112015001502B1 (pt) 2023-03-07
JP2019031542A (ja) 2019-02-28
HK1207302A1 (en) 2016-01-29
KR20150038295A (ko) 2015-04-08
EP2877177B1 (en) 2016-10-26
MA37866B1 (fr) 2016-12-30
PL2877177T3 (pl) 2017-04-28
HUE032919T2 (hu) 2017-11-28
JP2015522650A (ja) 2015-08-06
RS55646B1 (sr) 2017-06-30
LT2877177T (lt) 2017-01-25
SI2877177T1 (sl) 2017-02-28
CN104684554B (zh) 2017-05-10
AU2013294920A1 (en) 2015-03-12
AU2013294920B2 (en) 2017-08-24
RU2640046C2 (ru) 2017-12-26
BR112015001502A2 (pt) 2017-07-04
JP6732855B2 (ja) 2020-07-29
MX363605B (es) 2019-03-26
MY183398A (en) 2021-02-18
NZ705253A (en) 2017-05-26
MA37866A1 (fr) 2016-05-31
CY1118478T1 (el) 2017-07-12
ZA201501209B (en) 2016-03-30
JP6456823B2 (ja) 2019-01-23
RU2015106434A (ru) 2016-09-20
CA2879595C (en) 2020-07-28
ES2612349T3 (es) 2017-05-16
UA116107C2 (uk) 2018-02-12

Similar Documents

Publication Publication Date Title
ZA201501209B (en) Derivatives of azaindazole or diazaindazole type for treating pain
HUS1900040I1 (hu) Makrociklusos származékok proliferatív betegségek kezelésére
PT2879672T (pt) Terapia combinada para o tratamento da esclerose múltipla
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
IL233493A (en) Imidazopyridine derivatives for cancer treatment
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
IL237229A0 (en) Methods of treating cancer using lipoplatin
ZA201409502B (en) Composition for treatment of warts
GB201217890D0 (en) Treatment of cancer
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201208296D0 (en) Treatment of cancer
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment